CD40LG gene therapy (Editas Medicine)

N/A

Report date: 2025/08/14 17:46:50

Base Information

Drug NameCD40LG gene therapy (Editas Medicine)
Drug Alias NameN/A
ClassificationCell and gene therapy > Gene therapy > Gene editing > CRISPR > CRISPR-Cas9
Mechanisms of ActionCD40 ligand modulators
TargetsCD40 ligand
Therapy Area/IndicationsHyper-IgM Immunodeficiency Syndrome, Type 1
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesItaly
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesEditas Medicine Inc
China Registration ClassN/A

Develop Information

Active CompaniesEditas Medicine IncThe San Raffaele Telethon Institute For Gene Therapy
Inactive CompaniesN/A
Active IndicationsHyper-IgM Immunodeficiency Syndrome, Type 1
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A